BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Healome Therapeutics Raises £2 Million Seed Funding to Advance Eye-Drop Platform for Ocular Surface Diseases

Healome Therapeutics ("Healome"), a University of Birmingham spinout developing a proprietary eye-drop matrix technology for ocular surface diseases, has c...

July 09, 2026 | News

LG Chem and OTR Therapeutics Partner to Advance China-Sourced Oncology Assets Globally

OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today an...

July 09, 2026 | News

Singapore Updates Wegovy Label to Include Higher-Dose Semaglutide Data Showing Up to 25% Weight Loss

Up to one in three participants on semaglutide 7.2 mg achieved at least 25% weight loss over 72 weeks Mean weight loss with semaglutide 7.2 mg reached 2...

July 09, 2026 | News

Europe Approves TEPKINLY Combination as First Bispecific-Based Second-Line Therapy for Follicular Lymphoma

TEPKINLY® (epcoritamab) plus lenalidomide and rituximab (R2) is the first and only bispecific-based therapy approved in Euro...

July 08, 2026 | News

Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Portfolio

Agreement Part of Arima’s Long-Term Strategy to Focus on Core Diagnostic Platform and Tests Arima Genomics, Inc., a cancer diagnostics com...

July 07, 2026 | News

Immunomic Therapeutics Doses First Patient in Phase 1 Trial of saRNA Allergy Vaccine in Japan

First patient dosed less than one month after PMDA clearance, demonstrating rapid clinical execution Next-generation UNITE® saRNA-based immunother...

July 07, 2026 | News

Ever Supreme Advances Off-the-Shelf CAR-T Therapy CAR001 to Phase IIa After Positive Phase I Safety Review

Ever Supreme Bio Technology Co., Ltd. (TWSE: 6712) announced on June 28 that CAR001, its proprietarily developed, allogeneic, "off-the-shelf" CAR...

July 01, 2026 | News

NS Pharma Parent Nippon Shinyaku Secures Global Option Rights to Develop Elixirgen's DMD Therapy EXG-7001

NS Pharma, Inc. (NS Pharma; Headquarters, Paramus, NJ; President, Yukiteru Sugiyama) announced that its parent company, Nippon Shinyaku Co., Ltd. (Nippon S...

June 30, 2026 | News

Beyond the Obvious Giant: Where APAC's Clinical Trials Go Next

For most of the last decade, the strategic case for running Asia-Pacific clinical trials could be summarised in a single word: China. A vast, treatment-n...

June 29, 2026 | Analysis

Racura Oncology Doses First Patient in Phase 1 HARNESS-1 Trial of RC220 for EGFR-Mutant Lung Cancer

Racura Oncology has dosed the first patient in the HARNESS-1 Phase 1a/b trial of RC220 in combination with osimertinib for EGFR-mutant non-small cell lung ...

June 29, 2026 | News

Everest Medicines' LEROCHOL® BLA Accepted in China for Third-Generation PCSK9 Inhibitor

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...

June 29, 2026 | News

HKeyBio Launches NHP Fast-Tox Program to Accelerate Early Safety Assessment for Biologics

The program supports early tolerability assessment, PK/TK-linked safety evaluation, immune-related risk screening, and pre-GLP dose design for biologics an...

June 26, 2026 | News

Abbisko Therapeutics Expands Strategic Alliance with Lilly in Multi-Target Drug Discovery Deal Worth Up to $1.9 Billion

Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic research collab...

June 25, 2026 | News

AnHorn Medicines Secures FDA IND Clearance for First-in-Class CIPN Prevention Candidate

AnHorn Medicines announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuro...

June 24, 2026 | News

Stay Connected